March 18, 2020 – Pfizer Canada takes seriously the presence of the novel coronavirus (COVID-19) in Canada. In this troubling time, Pfizer is committed to doing all we can to respond to the COVID-19 pandemic. We are closely monitoring the impact of COVID-19 on our supply chain and as of now, we have not seen any disruption or impact to our business. We are working to ensure continued access of our medicines and vaccines to patients across Canada. We consistently and diligently monitor the supply of our medicines for preparedness and contingency planning to help ensure products are available for our patients. Furthermore, business continuity plans at our manufacturing sites have been invoked to ensure there is no disruption to supply. As of today, all our manufacturing sites are running at high capacity under a Pfizer-wide pandemic preparedness plan.